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Conclusion: There were no complications associated with TEI after AMI. This preliminary
data with a small number of animals suggests that NOGA guided TEI may be superior to
IC delivery. Thus, direct delivery of MSC's may play an important role even after an AMI .
1100-57 Catheter-Based Transplantation of Autologous Bone 
Marrow Mononuclear Cells Safely Improves Collateral 
and Capillary Network in Adult Swine With Myocardial 
Ischemia
Aysegul Yegin, Mio Ebato, Fernando Tondato, Bunken Ebato, Jianhua Cui, Traci 
Goodchild, Stephen C. Frohwein, Jesse Rios, James F. Sanzo, Keith Robinson, Mark 
Ungs, Nicolas A. Chronos, American Cardiovascular Research Institute, Atlanta, GA
Background: To date, it is unclear whether intramyocardial transplantation of autologous
bone marrow derived mononuclear cells (BM-MNCs) enhances neovascularization in
adult myocardium. We tested the hypothesis that catheter-based delivery of BM-MNCs
augments neovascularization in an adult porcine model of chronic ischemia. Methods:
Ameroid constrictor was implanted around proximal left circumflex coronary artery (LCX)
in adult Yucatan swine. Animals with LCX occlusion of < 90% were excluded from the
study. At 4 weeks, pigs were randomized to receive freshly isolated BM-MNCs (n=8) or
culture medium (DMEM) as control (n=8). Under general anesthesia, bone marrow (30-
50 ml) was aspirated from sternum and if necessary, iliac crest. Mononuclear cells were
isolated using density-gradient centrifugation method (Histopaque 1077). A total of 1 x
108 cells were injected at 10 sites (5 in the ischemic, and 5 in the non-ischemic region)
using Boston Scientific StilettoTM catheter with intracardiac echocardiography (ICE) guid-
ance. Baseline (4 wk) and follow-up (8 wk) evaluations included coronary angiography
(Rentrop score), dobutamine stress echocardiography, and myocardial blood flow by
microspheres. Tracking of BM-MNCs was performed in additional pigs (n=3). Tissue
samples were stained with PKH-26 to verify cell viability and DAPI (diamino-phenylin-
dole) for intact nuclear DNA, 2 and 4 weeks after delivery. Results: Collateral (Rentrop)
Scores: Left-to-left collaterals significantly improved in the BM-MNC treated group
(p=0.031). Cell tracking study: Ischemic areas contained higher amount of PKH-26 posi-
tive cells co-localizing with DAPI, compared to non-ischemic regions. Transplanted BM-
MNCs clustered in areas without abundant cellular structure. A significant increase was
found in total capillary area in the LCX (ischemic) region in endocardial (p=0.016) and
epicardial (p=0.044) sections in BM-MNC treated pigs compared to the control group.
Conclusion: Catheter-based intramyocardial transplantation of autologous BM-MNCs
safely enhances collateral and capillary network in adult swine with chronic myocardial
ischemia.
1100-58 Interpretation of the Actual Platelet Inhibition Induced 
by Clopidogrel: A New Look at How to Represent Drug 
Response
Paul A. Gurbel, Waiel M. Samara, Kevin P. Bliden, Sinai Center for Thrombosis 
Research, Baltimore, MD
Background: Mean pre- and post- treatment % platelet aggregation is commonly used
to describe clopidogrel- induced inhibition and may miss non-responders. Methods: Indi-
vidual responses to clopidogrel were studied by 5 µM ADP aggregation (A) in pts ( n = 68
) pre and at 5 days post-stenting. All pts received aspirin 325mg ; 300 mg clopidogrel at
the time of stenting ; and 75mg qd . A was recorded as the maximum % change in light
transmittance from baseline. Individual responses were measured at 5 days as the abso-
lute change in aggregation (∆ A) from pre-to post-treatment. (∆ A= pre-treatment A minus
post-treatment A ; non-response = ∆ A <10%.
Results: Pre-treatment A was 60 ± 17 and fell to 35 ± 17 after clopidogrel (p<.0001, 42%
relative inhibition ) and 16/68 patients (24%) were non-responders ( figure ). Non-
responders had higher platelet reactivity (p=.0002). However, total group A was not sig-
nificantly different from the group of responders ( p = .34 ). By reporting the data as ∆A
the presence of non- responders in unmasked (figure).
Conclusion: Non-responders are entirely unrecognized by the current practice of report-
ing mean aggregation data that overestimates the actual drug effect in certain patients.
Clinicians should be aware of non-response and its potential effect on outcomes. We rec-
ommend a more accurate approach to estimate the drug’s effect would be to account for
those patients who are non-responsive by reporting the individual change in aggregation
from pre-treatment to post-treatment. 
1100-59 High-Dose Clopidogrel Loading Rapidly Reduces Both 
Platelet Inflammatory Marker Expression and 
Aggregation
Frank J. Zidar, David J. Moliterno, Deepak L. Bhatt, Kandice Kottke-Marchant, Marelene 
Goormastic, Edward F. Plow, Eric J. Topol, Cleveland Clinic, Cleveland, OH
Background: Pretreatment with the platelet antagonist clopidogrel has been shown to
reduce short and long-term ischemic events after percutaneous coronary intervention.
The optimal clopidogrel loading dose and the timing of its benefit remain unclear. More-
over, it is uncertain whether these benefits are from inhibition of platelet-mediated aggre-
gation, inflammation, or both. We sought to determine the response to a 300mg
clopidogrel loading versus a 600mg (high dose) loading on the time-course of aggrega-
tion and inflammation suppression.
Methods: 12 healthy volunteers were given 300mg of clopidogrel, and blood samples
were obtained at baseline and 2, 4, and 6 hours. After a 2-week washout period, these
subjects were given 600mg of clopidogrel and serial blood sampling was repeated. Plate-
let aggregation was quantified using turbidimetric aggregometry with ADP (20uM) as the
agonist, and results were evaluated as percent inhibition of baseline aggregation. Platelet
CD40L and P-selectin expression in ADP-activated samples were quantified by flow
cytometry, and results were evaluated as percent positive cells. 
Results: Complete data were available on 10 subjects, 50% men with a mean of 35
years (+/- 7 SD). 
Conclusion: Beyond a greater early inhibition of platelet aggregation, a high loading 
dose of clopidogrel rapidly and more effectively suppresses platelet inflammatory mark-
ers. These anti-inflammatory effects likely play a key role in the clinical benefit from clopi-
dogrel pretreatment.
Control TEI IC
pre-cells post-cells pre-cells post-cells pre-cells post-cells
EDD(mm) 4.2±0.1 3.97±0.19 3.9±0.3 3.55±0.15 4.0±0.08 3.93±0.26
ESD(mm) 3.47±0.04 3.17±0.2 3.1±0.3 2.65±0.33 3.1±0.25 3±0.21
EF(%) 32±1.41 34±2.9 33±3.2 49±9 34±2.1 41±4.3
Ischemic 
Area(%LV)
19.8±4 20.4±8 37.9±9.8 6.8±5.3 25.8±11.7 6±4.3
Dose
(mg)
Time (hours) : Mean
0 2 4 6
% Inhibition
from baseline
aggregation
300 0 34.6 32.7 33.5
600 0 48.2* 43.9* 50.9*
Difference between 300 and 600 at 0 (p=NS), 2 (p=0.009), 4 (p=0.02), 6 (p=0.0008)
CD40L
% positive
cells
300 27.0 21.4 13.7 18.6
600 24.0 16.0 11.6 9.8*
Difference between 300 and 600 at 0, 2 and 4 hours (p=NS); 6 hours (p=0.01)
P-selectin
% positive
cells
300 88.6 84.1 82.4 81.9
600 81.1 75.7 72.3* 67.1*
Difference between 300 and 600 at 0 and 2 (p=NS), 4 hours (p=0.02), 6 hours (p=0.05)
